We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Indication Dosage form Strength
Levomethadone ** Severe pain Oral drops, solution 5mg/ ml (bottle 20ml)
Lisinopril Hypertension Tablets 5 and 20 mg
Lisinopril + HCTZ Hypertension Tablets 20/12.5 mg
Loratadine Allergy Film-coated tablets 10 mg
Melperone Psychomotor agitation and sleep Film-coated tablets 10 mg, 25 mg,  50mg and  100 mg
Melperone Forte Psychomotor agitation and sleep Oral solution 25mg/ 5 ml
Memantine hydrochloride Alzheimer's disease Film-coated tablets 5, 10, 15 and 20 mg
Memantine hydrochloride Alzheimer's disease Oral solution 10 mg/ml
Methocarbamol Muscle spasms, pain Film-coated tablets 750 mg
Methocarbamol Muscle spasms, pain Film-coated tablets 500, 1000 and 1500 mg
Midazolam Epilepsy Oral solution 2,5 mg/ 0,5 ml
5 mg/ 1 ml
7,5 mg/ 1,5 ml               
10 mg/ 2 ml
Montelukast Asthma, allergy Chewable tablets 4 and 5 mg
Montelukast Asthma, allergy Film-coated tablets 10 mg
Nabilone * Antiemetic Tablets 1 mg
Noxiall® Useful to contrast chronic and neuropathic pain Jan 2017
Olanzapine Psychosis, schizophrenia Film-coated tablets 2.5, 5, 7.5, 10, 15 and 20 mg
Olanzapine Psychosis, schizophrenia Orodispersable tablets 5, 10, 15 and 20 mg
Ondansetron Nausea & vomiting Film-coated tablets 4 and 8 mg
Ondansetron Nausea & vomiting Orodispersable tablets 4 and 8 mg
Opipramol Depression / Anxiety Film-coated tablets 50, 100 and 150 mg

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.